Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 11/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18800492 | 0.90 | BTK (0.48) | TNK2BTKADORA1ADORA2A | |
| SCHEMBL18800616 | 0.89 | BTK (0.47) | TNK2BTKADORA1ADORA2A | |
| SCHEMBL18800753 | 0.89 | BTK (0.49) | TNK2BTKADORA1ADORA2A | |
| SCHEMBL18800769 | 0.88 | ADORA2A (0.48) | TNK2BTKADORA1ADORA2AMAPT | |
| SCHEMBL18800882 | 0.87 | BTK (0.42) | TNK2BTKMAPTNPSR1 | |
| SCHEMBL18800641 | 0.86 | BTK (0.42) | TNK2BTKMAPTNPSR1 | |
| SCHEMBL18800755 | 0.86 | TNK2 (0.50) | TNK2BTK | |
| SCHEMBL18800585 | 0.86 | BTK (0.41) | TNK2BTK | |
| SCHEMBL18800574 | 0.86 | BTK (0.42) | TNK2BTKMAPTNPSR1 | |
| SCHEMBL18800748 | 0.86 | BTK (0.42) | TNK2BTKMAPTNPSR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2789615-B1 | Azaindazoles as Btk kinase modulators and use thereof | BRISTOL MYERS SQUIBB CO (US) | 2017-05-03 | — | — | EP | disclosed |